Nevirapine

奈韦拉平

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameNevirapine
Drug Alias Name奈维拉平nevirapinumNevirapine ER奈伟拉平Viramune Extended Release +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReverse transcriptase inhibitors
TargetsReverse transcriptase
Therapy Area/IndicationsPregnancy ComplicationsRenal InsufficiencyHepatic Insufficiency +[5] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date1996/06/21
Country/TerritoryBahamasBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim Pharma Gmbh & Co KgBoehringer Ingelheim International Gmbh
Inactive CompaniesThe Research Institute Of Tuberculosis (Japan)Harvard School Of Public HealthBamrasnaradura Infectious Diseases Institute +[7] 
Active IndicationsHIV Infections
Inactive IndicationsPregnancy ComplicationsRenal InsufficiencyHepatic Insufficiency +[4] 

Other Information

ATC CodeJ05AG01
Related LinksWikipediaDrugBankKEGG